Details for New Drug Application (NDA): 091102
✉ Email this page to a colleague
NDA 091102 describes CAFFEINE CITRATE, which is a drug marketed by Am Regent, Eugia Pharma, Exela Pharma Science, Fresenius Kabi Usa, Micro Labs, Sagent Pharms, Sun Pharm, and Exela Pharma, and is included in thirteen NDAs. It is available from seven suppliers. Additional details are available on the CAFFEINE CITRATE profile page.
The generic ingredient in CAFFEINE CITRATE is caffeine citrate. There are eleven drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the caffeine citrate profile page.
The generic ingredient in CAFFEINE CITRATE is caffeine citrate. There are eleven drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the caffeine citrate profile page.
Summary for 091102
| Tradename: | CAFFEINE CITRATE |
| Applicant: | Sagent Pharms |
| Ingredient: | caffeine citrate |
| Patents: | 0 |
Pharmacology for NDA: 091102
| Physiological Effect | Central Nervous System Stimulation |
Medical Subject Heading (MeSH) Categories for 091102
Suppliers and Packaging for NDA: 091102
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| CAFFEINE CITRATE | caffeine citrate | SOLUTION;ORAL | 091102 | ANDA | Sagent Pharmaceuticals | 25021-602 | 25021-602-03 | 10 VIAL in 1 CARTON (25021-602-03) / 3 mL in 1 VIAL |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | SOLUTION;ORAL | Strength | EQ 30MG BASE/3ML (EQ 10MG BASE/ML) | ||||
| Approval Date: | Aug 29, 2012 | TE: | AA | RLD: | No | ||||
Complete Access Available with Subscription
